Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Calaspargase Pegol-mknl, Decitabine, and Venetoclax in Relapsed/Refractory T-ALL and T-LLy
NCT06561074Phase 2Recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Sep 2025
- Primary completion
- Dec 2029
- Modality
- Small Molecules, Replacement Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of calaspargase pegol, decitabine, venetoclax in t-cell acute lymphoblastic leukemia (T-ALL), T cell lymphoblastic lymphoma (T-LBL), sponsored by University of Texas MD Anderson Cancer Center. Started Sep 2025; status: recruiting.
02
Drugs
calaspargase pegoldecitabinevenetoclax
03
Conditions
t-cell acute lymphoblastic leukemia (T-ALL)T cell lymphoblastic lymphoma (T-LBL)
Beyond the preview
Go deeper on NCT06561074.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06561074.